Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion type Assertion NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_head.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion description "[We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_provenance.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion evidence source_evidence_literature NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_provenance.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion SIO_000772 12640257 NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_provenance.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion wasDerivedFrom befree-20150227 NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_provenance.
- NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_assertion wasGeneratedBy ECO_0000203 NP230191.RAdfyiQCacWCZWrrrPR5R5KsgXt12FoSjxRK1ts8q4q78130_provenance.